# Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ca-25-004-advanced-development-and-validation-of-emerging-biospecimen/  
Official notice: https://www.grants.gov/search-results-detail/357737

> National Institutes of Health offered grants of up to $300,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 2 awards worth $300,000 in total. Applications closed on December 9, 2025.

| Field | Value |
|---|---|
| Opportunity number | RFA-CA-25-004 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | December 9, 2025 |
| Award ceiling | $300,000 |
| Award floor | not stated |
| Expected awards | 2 |
| Total funding | $300,000 |
| Cost sharing | not required |
| Assistance Listings | 93.394 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

Through this Notice of Funding Opportunity (NOFO), National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality and handling of samples used for cancer research or clinical care. Through this NOFO, NCI will support the development of tools, devices, assays, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and address issues related to pre-analytical degradation of of targeted analytes. Major feasibility gaps for the technology or methodology should have already been overcome, as demonstrated by supportive preliminary data, but the tool requires further development and rigorous validation. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

## Questions people ask

### Is RFA-CA-25-004 still open?

No. It closed on December 9, 2025.

### Who can apply for Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)?

Closed December 9, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $300,000 each. About $300,000 in total across about 2 awards.

### Who has been funded under RFA-CA-25-004?

NIH RePORTER lists 3 projects funded under RFA-CA-25-004 in fiscal 2026, at 3 institutions. The most were at Georgia Institute of Technology, Johns Hopkins University, Arizona State University-Tempe Campus.

### Who has won Cancer Detection and Diagnosis Research grants before?

The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.